Detalhe da pesquisa
1.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
2.
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation.
Blood
; 139(4): 584-596, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525179
3.
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Blood
; 139(8): 1208-1221, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34482403
4.
Top advances of the year: Leukemia.
Cancer
; 129(7): 981-985, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585394
5.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
6.
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Haematologica
; 108(10): 2616-2625, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37051756
7.
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Haematologica
; 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105738
8.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Ann Hematol
; 102(4): 749-754, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732419
9.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(5): 503-513, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156478
10.
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
Eur J Haematol
; 111(3): 365-372, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37254665
11.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
12.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
13.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
14.
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.
Blood
; 134(4): 389-394, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101624
15.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood
; 133(1): 7-17, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361262
16.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
17.
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.
Blood
; 134(11): 867-879, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31366621
18.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
J Natl Compr Canc Netw
; 19(1): 16-27, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33406488
19.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Am J Hematol
; 96(2): 208-217, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119898
20.
Hypomethylating agents with venetoclax: have we discovered the holy grail?
Curr Opin Hematol
; 27(2): 76-80, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31895103